Artivion, Inc. (AORT): who owns it and who trades it
As of Nov 16, 2026, AORT insiders reported 50 open-market sales worth $15.6M and no purchases in the last 12 months, with 26% of the sale value made under pre-set 10b5-1 plans. The largest seller was James P Mackin (CEO), with $7.4M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Artivion
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors and Congress mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AORT
205 funds and institutions reported AORT shares worth $1.1B at the end of Q2 2026, about 98% of the company. The largest holder is BlackRock, Inc. with 13.7%.
Funds and institutions (13F) 98%Everyone else 2%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 6.67M | 13.75% | $150M | +3% |
| Nomura Asset Management International Inc. | 3.18M | 6.56% | $71.6M | +30% |
| Morgan Stanley | 2.56M | 5.27% | $57.5M | +13% |
| Juniper Investment Company, LLC | 2.02M | 4.16% | $45.4M | +70% |
| Vanguard Capital Management LLC | 2.00M | 4.13% | $45M | +3% |
| FMR LLC (Fidelity) | 1.96M | 4.04% | $44.1M | -24% |
| State Street Corp | 1.86M | 3.83% | $41.8M | +10% |
| Ophir Asset Management Pty Ltd | 1.80M | 3.71% | $40.4M | +89% |
| Perceptive Advisors LLC | 1.74M | 3.58% | $39M | +6% |
| Conestoga Capital Advisors, LLC | 1.62M | 3.34% | $36.5M | +38% |
| Wellington Management Group LLP | 1.26M | 2.60% | $28.3M | +9% |
| California State Teachers Retirement System | 1.12M | 2.31% | $49.8M | +2087% |
| Geode Capital Management, LLC | 1.11M | 2.30% | $25M | -2% |
| Silvercrest Asset Management Group LLC | 1.02M | 2.11% | $23M | +55% |
| Vanguard Portfolio Management LLC | 988,219 | 2.04% | $22.2M | -5% |
| Dimensional Fund Advisors LP | 947,941 | 1.95% | $21.3M | -8% |
| Citadel Advisors LLC | 827,594 | 1.70% | $18.6M | +1068% |
| GW&K Investment Management, LLC | 794,478 | 1.64% | $17.9M | +8% |
| First Eagle Investment Management, LLC | 693,146 | 1.43% | $15.6M | +122% |
| Royce & Associates LP | 639,282 | 1.32% | $14.4M | +50% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AORT insiders reported $0 of open-market purchases and $15.6M of sales. 26% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Andrew M Green | Vice president | Sale | 11,480 | $24.97 | $287K | Form 4 |
| Sep 3, 2026 | Andrew M Green | Vice president | Sale | 1,493 | $26.02 | $38.8K | Form 4 |
| Sep 2, 2026 | Andrew M Green | Vice president | Sale | 6,510 | $27.27 | $178K | Form 4 |
| Aug 19, 2026 | James P Mackin | CEO | Sale | 70,000 | $28.96 | $2M | Form 4 |
| Aug 14, 2026 | Andrew M Green | Vice president | Sale | 616 | $28.55 | $17.6K | Form 4 |
| Aug 14, 2026 | Lance A Berry | CFO | Sale | 715 | $28.55 | $20.4K | Form 4 |
| Aug 12, 2026 | Jean F Holloway | Vice president | Sale | 977 | $28.49 | $27.8K | Form 4 |
| Jun 11, 2026 | Andrew M Green | Vice president | Sale plan | 30,000 | $20.69 | $621K | Form 4 |
| Jun 11, 2026 | Andrew M Green | Vice president | Sale plan | 14,001 | $20.71 | $290K | Form 4 |
| Mar 4, 2026 | Jean F Holloway | Vice president | Sale | 8,962 | $38.00 | $341K | Form 4 |
| Mar 3, 2026 | Amy Horton | Vice president | Sale | 901 | $37.78 | $34K | Form 4 |
| Mar 3, 2026 | Jean F Holloway | Vice president | Sale | 3,843 | $37.78 | $145K | Form 4 |
| Mar 3, 2026 | Marshall S. Stanton | Vice president | Sale | 2,149 | $37.78 | $81.2K | Form 4 |
| Mar 3, 2026 | John E Davis | Chief Commercial Officer | Sale | 4,573 | $37.78 | $173K | Form 4 |
| Mar 3, 2026 | Lance A Berry | CFO | Sale | 6,316 | $37.78 | $239K | Form 4 |
| Mar 3, 2026 | James P Mackin | CEO | Sale | 17,887 | $37.78 | $676K | Form 4 |
| Mar 2, 2026 | Amy Horton | Vice president | Sale | 641 | $38.02 | $24.4K | Form 4 |
| Mar 2, 2026 | Marshall S. Stanton | Vice president | Sale | 1,513 | $38.02 | $57.5K | Form 4 |
| Mar 2, 2026 | James P Mackin | CEO | Sale | 14,911 | $38.02 | $567K | Form 4 |
| Mar 2, 2026 | Jean F Holloway | Vice president | Sale | 2,183 | $38.02 | $83K | Form 4 |
| Mar 2, 2026 | Lance A Berry | CFO | Sale | 5,178 | $38.02 | $197K | Form 4 |
| Mar 2, 2026 | John E Davis | Chief Commercial Officer | Sale | 2,784 | $38.02 | $106K | Form 4 |
| Feb 24, 2026 | Amy Horton | Vice president | Sale | 830 | $35.69 | $29.6K | Form 4 |
| Feb 24, 2026 | Marshall S. Stanton | Vice president | Sale | 1,259 | $35.69 | $44.9K | Form 4 |
| Feb 24, 2026 | Jean F Holloway | Vice president | Sale | 1,668 | $35.69 | $59.5K | Form 4 |
| Feb 24, 2026 | James P Mackin | CEO | Sale | 13,936 | $35.69 | $497K | Form 4 |
| Feb 24, 2026 | Lance A Berry | CFO | Sale | 4,485 | $35.69 | $160K | Form 4 |
| Feb 24, 2026 | John E Davis | Chief Commercial Officer | Sale | 2,075 | $35.69 | $74.1K | Form 4 |
| Feb 23, 2026 | Amy Horton | Vice president | Sale | 1,731 | $37.59 | $65.1K | Form 4 |
| Feb 23, 2026 | Marshall S. Stanton | Vice president | Sale | 2,423 | $37.59 | $91.1K | Form 4 |
| Feb 23, 2026 | Jean F Holloway | Vice president | Sale | 3,079 | $37.59 | $116K | Form 4 |
| Feb 23, 2026 | James P Mackin | CEO | Sale | 20,962 | $37.59 | $788K | Form 4 |
| Feb 23, 2026 | Lance A Berry | CFO | Sale | 4,981 | $37.59 | $187K | Form 4 |
| Feb 23, 2026 | John E Davis | Chief Commercial Officer | Sale | 3,773 | $37.59 | $142K | Form 4 |
| Dec 15, 2025 | John E Davis | Chief Commercial Officer | Sale | 5,000 | $45.11 | $226K | Form 4 |
| Dec 8, 2025 | Amy Horton | Vice president | Sale | 4,572 | $44.42 | $203K | Form 4 |
| Dec 3, 2025 | James P Mackin | CEO | Sale plan | 30,921 | $45.46 | $1.4M | Form 4 |
| Dec 3, 2025 | Jean F Holloway | Vice president | Sale | 2,048 | $45.30 | $92.8K | Form 4 |
| Dec 3, 2025 | Jean F Holloway | Vice president | Sale | 5,267 | $45.30 | $239K | Form 4 |
| Dec 2, 2025 | James P Mackin | CEO | Sale plan | 30,921 | $45.56 | $1.4M | Form 4 |
| Nov 21, 2025 | Marshall S. Stanton | Vice president | Sale | 18,705 | $44.91 | $840K | Form 4 |
| Nov 21, 2025 | Marshall S. Stanton | Vice president | Sale | 8,370 | $45.35 | $380K | Form 4 |
| Nov 21, 2025 | Marshall S. Stanton | Vice president | Sale | 14,586 | $44.92 | $655K | Form 4 |
| Nov 21, 2025 | Marshall S. Stanton | Vice president | Sale | 5,715 | $45.35 | $259K | Form 4 |
| Nov 20, 2025 | Marshall S. Stanton | Vice president | Sale | 1,355 | $44.28 | $60K | Form 4 |
| Nov 20, 2025 | Marshall S. Stanton | Vice president | Sale | 2,033 | $44.32 | $90.1K | Form 4 |
| Nov 20, 2025 | Marshall S. Stanton | Vice president | Sale | 11,888 | $44.14 | $525K | Form 4 |
| Nov 18, 2025 | Elizabeth A Hoff | Director | Sale | 4,200 | $45.10 | $189K | Form 4 |
| Nov 17, 2025 | Jean F Holloway | Vice president | Sale plan | 6,394 | $45.17 | $289K | Form 4 |
| Nov 17, 2025 | Amy Horton | Vice president | Sale | 6,000 | $45.73 | $274K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| James P Mackin | President & CEO | – | $7.4M | Aug 19, 2026 |
| Marshall S. Stanton | SVP, Clinical & MD Affair | – | $3.1M | Mar 3, 2026 |
| Andrew M Green | SVP, Regulatory and Quality | – | $1.4M | Sep 10, 2026 |
| Jean F Holloway | SVP, General Counsel | – | $1.4M | Aug 12, 2026 |
| Lance A Berry | EVP, COO, CFO & Treasurer | – | $803K | Aug 14, 2026 |
| John E Davis | Chief Commercial Officer | – | $720K | Mar 3, 2026 |
| Amy Horton | VP, Chief Accounting Officer | – | $631K | Mar 3, 2026 |
| Elizabeth A Hoff | Director | – | $189K | Nov 18, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AORT short interest
Moderate short interest. 7.0% of AORT shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 76%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.41M AORT shares were sold short, 7.0% of the shares outstanding, down 8.6% from the report before. At the average daily volume of 472,904 shares, buying them all back would take about 7.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.41M | 6.99% | -9% | 472,904 | 7.2 |
| Oct 15, 2026 | 3.74M | 7.66% | +3% | 517,233 | 7.2 |
| Sep 30, 2026 | 3.62M | 7.43% | +10% | 654,874 | 5.5 |
| Sep 15, 2026 | 3.28M | 6.74% | +12% | 604,535 | 5.4 |
| Aug 31, 2026 | 2.93M | 6.00% | +7% | 662,170 | 4.4 |
| Aug 14, 2026 | 2.75M | 5.63% | +1% | 857,370 | 3.2 |
| Jul 31, 2026 | 2.71M | 5.55% | +8% | 568,148 | 4.8 |
| Jul 15, 2026 | 2.50M | 5.15% | +15% | 550,079 | 4.5 |
| Jun 30, 2026 | 2.18M | 4.49% | +15% | 1.08M | 2.0 |
| Jun 15, 2026 | 1.89M | 3.89% | -1% | 810,012 | 2.3 |
| May 29, 2026 | 1.92M | 3.95% | -1% | 679,115 | 2.8 |
| May 15, 2026 | 1.94M | 4.00% | +1% | 1.14M | 1.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded AORT
Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 1 sale of AORT. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Aug 20, 2026, reported Sep 10, 2026.
Purchases 2Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 10, 2026 | Report |
| Jul 16, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 4, 2026 | Report |
| Oct 9, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Nov 18, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Artivion company events
Artivion filed 6 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- May 18, 2026AnnouncementArtivion completed its previously announced acquisition of Endospan pursuant to the exercise of Artivion’s option to purchase (directly or indirectly through an affiliate) all of the outstanding securities of Endospan. Filing
- May 15, 2026VoteReported shareholder vote results. Filing
- May 7, 2026AgreementSecurities Purchase Option Agreement As previously disclosed in connection with the announcement of the Exclusive Distribution Agreement, dated September 11, 2019, between JOTEC GmbH, a wholly owned subsidiary of Artivion, Inc., a Delaware corporation formerly known as CryoLife, Inc., and Endospan… Filing
- Feb 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Artivion financials
Famous investors that hold AORT
4 of the 50 well-known investors we track reported holding AORT in their latest 13F filing. The largest position is Ken Griffin's, worth $26.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.14M | $26.1M | 0.0% | +38% |
| Israel Englander · Millennium Management | Q3 2026 | 559,095 | $12.8M | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 41,532 | $948K | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 10,900 | $249K | 0.0% | -84% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named AORT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 14.7% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 14.7% |
Questions about Artivion, Inc. (AORT) stock
Who owns the most AORT stock?
The largest reported owner of Artivion, Inc. (AORT) is BlackRock, Inc., with 13.7% of the company. In total, 205 funds and institutions reported holding AORT at the end of Q2 2026, together about 98% of the shares. See the largest owners.
Are AORT insiders buying or selling?
In the last 12 months, AORT insiders reported no open-market purchases and 50 sales worth $15.6M. The latest trade was on Sep 10, 2026. See every trade.
What is the short interest in AORT?
As of Oct 30, 2026, 3.41M AORT shares were sold short, 7.0% of the shares outstanding, down 8.6% from the report before. At the average daily volume of 472,904 shares, buying them all back would take about 7.2 trading days (days to cover). See the history.
Have members of Congress traded AORT?
Yes. 1 member of Congress reported 2 purchases and 1 sale of AORT since Nov 17, 2024. The latest was reported on Sep 10, 2026. See the trades.
Which famous investors hold AORT?
4 of the 50 well-known investors we track reported AORT in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $26.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.